Pneumococcal polysaccharide vaccine

Mar 26, 2020

SutroVax Announces $110M Series D Financing to Advance Broadest-Spectrum Pneumococcal Vaccine Candidates to Prevent Pneumonia

Jan 30, 2020

United States' $9 Billion Pneumonia Vaccine Industry, 2020-2026 - Major Players are Merck, Pfizer, GlaxoSmithKline (GSK), LG Chem, and SK Chemical (Sanofi Pasteur)

Nov 27, 2019

Global pneumococcal vaccines market is expected to grow with a CAGR of 3.3% over the forecast period from 2019-2025

Jul 12, 2019

Pneumonia Vaccines Market to Reach $9.6 Billion by 2025 - Rise in Government Focus on Immunization Programs is a Key Driver

Jun 18, 2019

Global Pneumococcal Vaccines Market and Forecast Analysis 2018-2022: V114 and GSK-3 will Threaten the Dominance of Prevnar 13 with Potential for Broader Coverage, Starting in 2022

Jul 24, 2018

Pneumococcal Vaccines Market is Projected to Register a CAGR of 9.1% Over the Forecast Period 2018 -2028

Jun 07, 2018

SutroVax Announces $85M Series C Financing led by TPG Growth

Apr 30, 2018

Sinovac Forced to Plan to Destroy Bacterial Seeds intended for Pneumo Vaccine Production and Postpone Site Inspection

Oct 12, 2017

Sinovac Completed its 23-Valent Pneumococcal Polysaccharide Vaccine Phase III Clinical Trial and Filed the New Drug Application to CFDA

Oct 11, 2017

SutroVax Appoints Veteran Vaccine Experts to Executive Team

Sep 27, 2017

Just Over Half of Adults with Work-Related Asthma Report Having Received a Pneumococcal Vaccine